United Therapeutics Corporation (UTHR) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Group 1 - The company has a growing existing commercial business, reporting double-digit annual growth last year, which is expected to continue moving forward [2] - Over the next 18 months, the company is poised to launch significant drugs, including ralinepag for pulmonary arterial hypertension (PAH) and Tyvaso for idiopathic pulmonary fibrosis (IPF) [3]